Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 4/12/2020
SIETES contiene 93177 citas

 
 
 1 a 19 de 19 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Nguyen TNM, Laetsch DC, Chen L-J, Haefeli WE, Meid AD, Brenner H, Schöttker B. Pain severity and analgesics use in the community-dwelling older population: a drug utilization study from Germany. Eur J Clin Pharmacol 2020;76:. [Ref.ID 103779]
2. Cita con resumen
Maxwell S, Eichler H-G, Bucsics A, Haefeli WE, Gustafsson LL. e-SPC - delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers. Br J Clin Pharmacol 2012;73:12-5. [Ref.ID 92246]
3.Enlace a cita original
Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010;66:marzo. [Ref.ID 88031]
4.
Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol 2006;62:1065-73. [Ref.ID 78697]
5.
Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 2005;61:327-35. [Ref.ID 74486]
6.
7.
Martin-Facklam M, Rieger K, Riedel K-D, Burhenne J, Walter-Sack I, Haefeli WE. Undeclared exposure to St. John's wort in hospitalized patients. Br J Clin Pharmacol 2004;58:437-41. [Ref.ID 71526]
8.
Rieger K, Scholer A, Arnet I, Peters F T, Maurer HH, Walter-Sack I, Haefeli WE, Martin-Facklam M. High prevalence of unknown co-medication in hospitalised patients. Eur J Clin Pharmacol 2004;60:363-8. [Ref.ID 71052]
9.
10.
Schneider V, Henschel V, Tadjalli-Mehr K, Mansmann U, Haefeli WE. Impact of serum creatinine measurement error on dose adjustment in renal failure. Clin Pharmacol Ther 2003;74:458-67. [Ref.ID 68307]
11.Tiene citas relacionadas Cita con resumen
Tayrouz Y, Ding R, Burhenne J, Riedel K-D, Weiss J, Hoppe-Tichy T, Haefeli WE, Mikus G. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther 2003;73:397-504. [Ref.ID 65895]
12. Cita con resumen
Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med 2001;161:2021-6. [Ref.ID 58837]
13. Cita con resumen
Arnet I, Haefeli WE. Overconsumption detected by electronic drug monitoring requires subtle interpretation. Clin Pharmacol Ther 2000;67:44-7. [Ref.ID 49370]
14. Cita con resumen
Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhadbomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998;351:1929-30. [Ref.ID 39100]
15.
Tamm M, Sieber C, Schnyder F, Haefeli WE. Moxonidine-induced cholestatic hepatitis. Lancet 1997;350:1822. [Ref.ID 36527]
16. Cita con resumen
Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, Meyer UA, Haefeli WE. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996;60:62-7. [Ref.ID 29308]
17.
Schlienger RG, Saxer M, Haefeli WE. Reversible ageusia associated with losartan. Lancet 1996;347:471-2. [Ref.ID 25998]
18. Cita con resumen
Bauer TM, Ritz R, Haberthür C, Ha HR, Hunkeler W, Sleight AJ, Scollo-Lavizzari G, Haefeli WE. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995;345:145-7. [Ref.ID 24550]
19.
Schoenenberger RA, Haefeli WE, Weiss P, Ritz R F. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). BMJ 1990;300:1375-6. [Ref.ID 12984]
Seleccionar todas
 
 1 a 19 de 19